臨床醫(yī)學(xué)專業(yè)碩士論文參考文獻(xiàn)
臨床醫(yī)學(xué)專業(yè)碩士論文參考文獻(xiàn)一
[1]Weaver A., da Silva A. G, Nuttall R. K.，et al. An elevated matrix metalloproteinase(MMP) in an animal model of multiple sclerosis is protective by affecting Thl/Th2polarization. The FASEB journal. 2005. 19(12): p. 1668-1670.
[2]Venteo L_，Bourlet T” Renois F” et al. Enterovirus-related activation of thecardiomyocyte mitochondrial apoptotic pathway in patients with acute myocarditis.European heart journal. 2010. 31(6): p. 728-736.
[3]Rose N. R. The adjuvant effect in infection and autoimmunity. Clinical reviews inallergy & immunology. 2008. 34(3): p. 279-282.
[4]陳瑞珍，解玉泉.病毒性心肌炎向擴(kuò)張型心肌病演變的免疫學(xué)機(jī)制.診斷學(xué)理論與實(shí)踐-2012. 10(5): p. 414-417.
[5]Camporeale A., Marino F” Papageorgiou A.，et al. STAT3 activity is necessary andsufficient for the development of immune “ mediated myocarditis in mice andpromotes progression to dilated cardiomyopathy. EMBO molecular medicine. 2013.5(4): p. 572-590.
[6]Zhu J.,Paul W. E. CD4 T cells: fates, functions, and faults. Blood. 2008. 112(5): p.1557-1569.
[7]Korn T.，Bettelli E?，Oukka M.，et al. IL-17 and Thl7 Cells. Annual review ofimmunology. 2009. 27: p. 485-517.
[8]Yu Y” Liu Y-，Shi F.-D., et al. Cutting edge: leptin-induced RORyt expression in CD4+T cells promotes Thl7 responses in systemic lupus erythematosus. The Journal ofImmunology. 2013. 190(7): p. 3054-3058.
[9]van Bruggen N.,Ouyang W. Thl7 Cells at the Crossroads of Autoimmunity,Inflammation, and Atherosclerosis. Immunity. 2014. 40(1): p. 10-12.
[10]Annnn2:iatoF., Cosmi L., Santarlasci V.，et al. Phenotypic and functional features ofhuman Thl7 cells. The Journal of experimental medicine. 2007. 204(8): p. 1849-1861.
[11]ShahraraS.，Huang Q.，Mandelin II A. M.，et al. TH-17 cells in rheumatoid arthritis.Arthritis Research and Therapy. 2008. 10(4): p. R93.
[12]KomiyamaY.，Nakae S.，Matsuki T_，et al. IL-17 plays an important role in thedevelopment of experimental autoimmune encephalomyelitis. The Journal ofImmunology. 2006. 177(1): p. 566-573.
[13]Bettelli E” Carrier Y?，Gao W，et al. Reciprocal developmental pathways for thegeneration of pathogenic effector TH17 and regulatory T cells. Nature. 2006.441(7090): p. 235-238.
[14]VeldhoenM.，Hocking R. J.，Atkins C. J.，et al. TGFp in the context of aninflammatory cytokine milieu supports de novo differentiation of IL-17-producing Tcells. Immunity. 2006. 24(2): p. 179-189.
[15]ManganP. R., Harrington L. E.，O'Quinn D. B.，et al. Transforming growth factor-pinduces development of the TH17 lineage. Nature. 2006. 441(7090): p. 231-234.
[16]AkimzhanovA. M.，Yang X. 0.,Dong C. Chromatin remodeling of interleukin-17(IL-17)-IL-17F cytokine gene locus during inflammatory helper T cell differentiation.Journal of biological chemistry. 2007. 282(9): p. 5969-5972.
[17]NurievaR” Yang X. 0” Martinez G，et al. Essential autocrine regulation by IL-21 inthe generation of inflammatory T cells. Nature. 2007. 448(7152): p. 480-483.
[18]Yang L，Anderson D. E.，Baecher-Allan C.，et al. IL-21 and TGF-&bgr; are requiredfor differentiation of human TH17 cells. Nature. 2008.454(7202): p. 350-352.
[19]TrinchieriG，Pflanz S.,Kastelein R. A. The IL-12 family of heterodimeric cytokines:new players in the regulation of T cell responses. Immunity. 2003. 19(5): p. 641-644.
[20]Zhou L，Ivanov I. I，Spolski R?，et al. IL?6 programs TH-17 cell differentiation bypromoting sequential engagement of the IL-21 and IL-23 pathways. Natureimmunology. 2007. 8(9): p. 967-974.
[21]AggarwalS” Ghilardi N., Xie M.-H.，et al. Interleukin-23 promotes a distinct CD4 Tcell activation state characterized by the production of interleukin-17. Journal ofBiological Chemistry. 2003. 278(3): p. 1910-1914.
[22]Harrington L. E., Hatton R. D.，Mangan P. R.，et al. Interleukin 17—producing CD4+effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages.Nature immunology. 2005. 6(11): p. 1123-1132.
[23]Yang X. 0., Panopoulos A. D.，Nurieva R.，et al. STAT3 regulates cytokine-medlatedgeneration of inflammatory helper T cells. Journal of Biological Chemistry. 2007.282(13): p. 9358-9363.
[24]LaurenceA.，Tato C. M.，Davidson T. S?，et al. Interleukin-2 signaling via STAT5constrains T helper 17 cell generation. Immunity. 2007. 26(3): p. 371-381.
[25]EberlG，Marmon S.，Sunshine M.-J.，et al. An essential function for the nuclearreceptor RORyt in the generation of fetal lymphoid tissue inducer cells. Natureimmunology. 2004. 5(1): p. 64-73.
[26]Yang X. 0” Pappu B. P.，Nurieva R., et al. T helper 17 lineage differentiation isprogrammed by orphan nuclear receptors RORa and RORy. Immunity. 2008. 28(1): p.29-39.
[27]IvanovI. I.，McKenzie B. S.，Zhou L.，et al. The Orphan Nuclear Receptor RORytDirects the Differentiation Program of Proinflammatory IL-17< sup>+ T HelperCells. Cell. 2006. 126(6): p. 1121-1133.
[28]QingK.，Weifeng W” Fan Y?，et al. Distinct different expression of Thl7 and Th9 cellsin coxsackie virus B3-induced mice viral myocarditis. Wol J. 2011. 8: p. 267.
[29]Jiang N.，Liao W”Kuang X. Effects of emodin on IL-23/IL-17 inflammatory axis，Thl7 cells and viral replication in mice with viral myocarditis. Nan Fang Y Ke DaXue Xue Bao. 2014. 34(3): p. 373-378.
[30]Yang F.，Wu W.-F.，Yan Y.-L.，et al. Expression of il-23/thl7 pathway in a murinemodel of coxsackie virus b3-induced viral myocarditis. Virology journal. 2011. 8(1): p.301.
[31]FanY” Weifeng W., Yuluan Y” et al. Treatment with a neutralizing anti-murineinterleukin-17 antibody after the onset of coxsackievirus b3-induced viral myocarditisreduces myocardium inflammation. Virol J. 2011. 8(1): p.17.
[32]Yu M.5 Hu J” Zhu M. X.，et al. Cardiac fibroblasts recruit Thl7 cells infiltration intomyocardium by secreting CCL20 in CVB3-induced acute viral myocarditis. CellPhysiol Biochem. 2013. 32(5): p, 1437-1450.
[33]XieY.，Chen R.，Zhang X.，et al. The role of Thl7 cells and regulatory T cells inCoxsackievirus B3-induced myocarditis. Virology. 2011. 421(1): p. 78-84.
[34]YuanJ., Yu M., Lin Q.-W., et al. Thl7 cells contribute to viral replication incoxsackievirus B3-induced acute viral myocarditis. The Journal of Immunology. 2010.185(7): p. 4004-4010.
[35]YuanJ.，Cao A.-L., Yu M.，et al. Thl7 cells facilitate the humoral immune response inpatients with acute viral myocarditis. Journal of clinical immunology. 2010. 30(2): p.226-234.
[36]Yuan J” Yu M.，Lin Q.-W., et al. Neutralization of IL-17 inhibits the production ofanti-ANT autoantibodies in CVB3-induced acute viral myocarditis. Internationalimmunopharmacology. 2010.10(3): p. 272-276.
[37]Liu Y?，Zhu H?，Su Z.，et al. IL-17 contributes to cardiac fibrosis followingexperimental autoimmune myocarditis by a PKCbeta/Erkl/2/NF-kappaB_dependentsignaling pathway. Int Immunol. 2012. 24(10): p. 605-612.
[38]BaldevianoG C., Barin J. G，Talor M. V” et al. Interleukin-17A is dispensable formyocarditis but essential for the progression to dilated cardiomyopathy. Circulationresearch. 2010. 106(10): p. 1646-1655.
臨床醫(yī)學(xué)專業(yè)碩士論文參考文獻(xiàn)二
[1]Lopshire JC，Zipes DP. Sudden cardiac death: better understanding of risks,mechanisms, and treatment[J]. Circulation, 2006, 114(11): 1134-1136
[2]Zipes DP, Camm AJ, Borggrefe M，et al. ACC/AHA/ESC 2006 guidelines formanagement of patients with ventricular arrhythmias and the prevention of sudden cardiacdeath: a report of the American College of Cardiology/American Heart Association TaskForce and the European Society of Cardiology Committee for Practice Guidelines (WritingCommittee to Develop Guidelines for Management of Patients Wilh VentricularArrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol, 2006，48(5):e247-e346.
[3]Fishman GI，Chugh SS, Dimarco JP，et al. Sudden cardiac death prediction andprevention: report from a National Heart, Lung, and Blood Institute and Heart RhythmSociety Workshop [J]. Circulation, 2010，122(22); 2335-2348.
[4]Go AS, Mozaffarian D，Roger VL, et al. Heart disease and stroke statistics-2014 update:a report from tiie American Heart Association[J]. Circulation, 2014，129(3): e28-e292.
[5]Hua W, Zhang LF, Wu YF, et al. Incidence of sudden cardiac death in china: analysis of4 regional populations [J], J Am Coll Cardiol, 2009，54(12): 1110-1118.
[6]Gillum RF. Geographic variation in sudden coronary death[J]. Am Heart J，1990，119(2Pt 1): 380-389.
[7]Huikuri HV, Castellanos A，Myerburg RJ.Sudden death due to cardiac arrhythmias [J] .NEngl J Med, 2001, 345(20); 1473-1482.
[8]Fox CS, Evans JC, Larson MG, et al. Temporal trends in coronary heart diseasemortality and sudden cardiac death from 1950 to 1999: the Framingham Heart Study [J],Circulation，2004，110(5): 522-527.
[9]Ford ES, Ajani UA, Croft JB，et al. Explaining the decrease in U.S. deaths fromcoronary disease, 1980-2000[J]. N Engl J Med，2007，356(23): 2388-2398.
[10]Dudas K，Lappas G, Stewart S, et al. Trends in out-of-hospital deaths due to coronaryheart disease in Sweden (1991 to 2006)[J]. Circulation, 2011，123(1): 46-52.
[11]Gerber Y，Jacobsen SJ，F(xiàn)rye RL, et al. Secular trends in deaths from cardiovasculardiseases: a 25-year community study [J]. Circulation, 2006，113(19): 2285-2292.
[12]Cupples LA, Gagnon DR, Kannel WB. Long- and short-term risk of sudden coronarydeath[J]. Circulation, 1992，85(1 Suppl); 111-8.
[13]Farb A，Tang AL, Burke AP，et al. Sudden coronary death. Frequency of activecoronary lesions, inactive coronary lesions, and myocardial infarction[J]. Circulation, 1995，92(7): 1701-1709.
[14]Ifteni P，Correll CU, Burtea V，et al. Sudden unexpected death in schizophrenia:Autopsy findings in psychiatric inpatients[J]. Schizophr Res，2014，Epub ahead of print.
[15]Virmani R，Burke A，F(xiàn)arb A. Coronary risk factors and plaque morphology in menwith coronary disease who died suddenly [J]. Eur Heart J，1998,19(5): 678-680.
[16]Josephson M，Wellens HJ. Implantable defibrillators and sudden cardiac death[J].Circulation, 2004, 109(22):2685-2691.
[17]Roes SD, Borleffs CJ, van der Geest RJ，et al. Infarct tissue heterogeneity assessedwith contrast-enhanced MRI predicts spontaneous ventricular arrhythmia in patients withischemic cardiomyopathy and implantable cardioverter-defibrillator[J]. Circ CardiovascImaging, 2009,2(3): 183-190.
[18]Holmberg M，Holmberg S，Herlitz J. Incidence，duration and survival of ventricularfibrillation in out?of-hospital cardiac arrest patients in Sweden [J]. Resuscitation, 2000,44(1); 7-17.
[19]Schatzkin A，Cupples LA, Heeren T，et al. The epidemiology of sudden unexpecteddeath: risk factors for men and women in the Framingham Heart Study. Am Heart J, 1984,107(6): 1300-1306.
[20]Patel RS, Ye S. Genetic determinants of coronary heart disease: new discoveries andinsights from genome-wide association studies[J]. Heart, 2011,97(18): 1463-1473.
[21]Swerdlow DI, Holmes MV，Harrison S，et al. The genetics of coronary heart disease[J].Br Med Bull, 2012, 102: 59-77.
[22]Sandhu RK, Jimenez MC，Chiuve SE, et al. Smoking, smoking cessation, and risk ofsudden cardiac death in women [J]. Circ Arrhythm Electrophysiol, 2012，5(6); 1091-1097.
[23]Wannamethee G, Shaper AG. Alcohol and sudden cardiac death [J]. Br Heart J, 1992,68(5): 443-448.
[24]Bertoia ML, Triche EW, Michaud DS，et al. Long-term alcohol and caffeine intake andrisk of sudden cardiac death in women [J]. Am J Clin Nutr, 2013, 97(6): 1356-1363.
[25]Reno CM, Daphna-Iken D，Chen YS, et al. Severe hypoglycemia-induced lethalcardiac arrhythmias are mediated by sympathoadrenal activation[J]. Diabetes, 2013，62(10):3570-3581.
[26]Tanaka F, Makita S，Onoda T, et al. Predictive value of lipoprotein indices for residualrisk of acute myocardial infarction and sudden death in men with low-density lipoproteincholesterol levels<120 mg/dl[J]. Am J Cardiol, 2013，112(8): 1063-1068.
[27]Rahimi K, Majoni W, Merhi A, et al. Effect of statins on ventricular tachyarrhythmia,cardiac arrest, and sudden cardiac death: a meta-analysis of published and unpublishedevidence from randomized trials [J]. Eur Heart J, 2012, 33(13): 1571-1581.
[28]Vasiliadis I，Kolovou G, Mavrogeni S, et al. Sudden cardiac death and diabetesmellitus[J]. J Diabetes Complications, 2014, Epub ahead of print.
[29]McMurray JJ, Adamopoulos S, Anker SD，et al. ESC Guidelines for the diagnosis andtreatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis andTreatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology.Developed in collaboration with the Heart Failure Association (HFA) of the ESC [J]. EurHeart J, 2012，33(14): 1787-1847.
[30]Anderson JL，Adams CD, Antman EM, et al. 2012 ACCF/AHA focused updateincorporated into the ACCF/AHA 2007 guidelines for the management of patients withunstable angina/ non-ST-elevation myocardial infarction: a report of the American Collegeof Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. JAm Coll Cardiol, 2013，61(23): el79-347.
[31]Laukkanen J A, Makikallio TH, Rauramaa R, et al. Asymptomatic ST-segmentdepression during exercise testing and the risk of sudden cardiac death in middle-aged men:a population- based follow-up study [J]. Eur Heart J, 2009,30(5): 558-565.
[32]Aro AL, Anttonen O, Tikkanen JT, et al. Intraventricular conduction delay in astandard 12-lead electrocardiogram as a predictor of mortality in the general population[J].Circ Arrhythm Electrophysiol, 2011, 4(5): 704-710.
[33]Yu H, Pi-Hua F, Yuan W, et al. Prediction of sudden cardiac death in patients afteracute myocardial infarction using T-wave altemans: a prospective study [J], J Electrocardiol,2012，45(1): 60-65.
[34]Santangeli P, Infusino F, Squeglia GA, et al. Ventricular late potentials:critical^overview and current applications [J]. J Electrocardiol, 2008，41(4): 318-324.
[35]Nagata M, Ninomiya T，Doi Y，et al. Temporal trends in sudden unexpected death in ageneral population: the Hisayama study [J]. Am Heart J, 2013,165(6): 932-938.
[36]Cerrone M, Priori SG. Genetics of sudden death: focus on inherited channelopathies[J].Eur Heart J, 2011, 32(17): 2109-2118.
[37]Jacoby D, McKeima WJ. Genetics of inherited cardiomyopaUiy[J]. Eur Heart J, 2012，33(3): 296-304.
[38]Puri A, Chaudhary Q Srivastava R, et al. Electrical disturbance in heart by smokelesstobacco[J]. J Assoc Physicians India, 2013, 61(5): 332-334.
[39]Piccini JP, Zhang M, Pieper K，et al. Predictors of sudden cardiac death change withtime after myocardial infarction: results from the VALIANT trial[J]. Eur Heart J, 2010，31(2):211-221.
[40]Zaman S, Narayan A, Thiagalingam A, et al. What is the optimal left ventricularejection fraction cut-off for risk stratification for primary prevention of sudden cardiacdeath early after myocardial infarction[J] Europace, 2014，Epub ahead of print.
臨床醫(yī)學(xué)專業(yè)碩士論文參考文獻(xiàn)三
1、Pistolesi S, Boldrini L, GisfrediS, etal. Angiogenesis in intraeranialmeningJomas：immunohistochemieal and molecular study[J]. Neuro. pathol Appl NeumbioL 2004,30(2): 118-125
2、Samoto K, Ikezaki K, OnoM，etal. Expression of Vascular endothdialgrowth factorand its possible relation with neovascularizafion in human brain tumor. Cancer Rea,1995，55： 1189-1193.
3、Dufy JPj EiblG，Reber HA, etal. Influence of hypoxia and neoangiogenesis on thegrowth of pancreatic cancer[J]. Mol Cancer, 2003 , 2(1)： 12
4、Brekken RA> Oven holser JP, Stasny VA, etal. Selective inhibition of vascularendothelial growth factor(VEGF)receptor 2 (KDR/Flk-2) activity by a monoclonalanti-VEGF antibody blocks tumor growth in mice[J]. Cancer Res, 2000, 60(18)：5117-5124.
5、Bullard LE，Qix，Penn JS. Role for extracellular signal-responsive kinase-1 and-2 inretinal angiogenesis[J]. Invest Opthol Vis Sci, 2003，44(4)： 1722-1731.
6、Strugar JG, Criscuolo GR，Rothbart D, et al. Vascular endothelialgrowth/permeabilityfactor expression in human glioma specimens： cotrelation with vasogenic brain edemaand tumor~associated cysts[J]. JNeuresurg, 1995，83(4)： 682-689.
7、Goldman CK, Bharaxa S，Palmer CA，et al. Brain edema in meningiomasis associatedwith increased vascular endothelial growth factor ex~pression[J]. Neuresurgery, 1997，40(6)： 1269-1277.
8、Fumiyuki Y, Hireyuki Y, Seiji H, etal. Recurrence ofMeningiomas： Influence ofvascular endothelial growth factor expression[J]. Cancer, 2000. 89(5)： 1102-1110.
9、黃強(qiáng).膠質(zhì)瘤[M].北京：中國(guó)科學(xué)山版社.2/360.50-60.
10、Williamns.EG，Moran EM. Epidemiological and clini cal aspect s of nonst eroidalant-inflammatory drags and cancer ris ks [ J] J Environ Pathol Toxicol Oncol, 2002，21(2):193-221
11、步星耀.章翔，易聲禹.膠質(zhì)瘤VEGF基因表達(dá)與血管生成和腦水腫的關(guān)系[J].中華神經(jīng)外科雜志2002. 17： 21
12、Arboix A, Val-1 LI osera A, Garcia-Er ol es L, et all Clinical features and functi onalout come of int racerebral hemorrhage in patient's aged 85 and older [J] J Am GeriatrSoc，2002，50( 3 ): 449- 454.
13、Xu XC. COX- 2 inhibitors in cancer treatment and prevention, a recent development[J ]. Anticancer Drugs, 2002，13( 2): 127-137.
14、Hirai H, Maru Y, Hagiwara K, et al. A novel putativetyrosine kinase receptor encodedby the ephgene[J]. Science, 1987, 238(4834)： 1717.
15、Himanen JP, Henkemeyer M, NikolovDB. Crystal structure of the ligand~bindingdomain of the receptor tyrosine kinase EphB2[J]. Nature, 1998，396(6710)： 486
16、Eph Nomenclature Committee[letter]. Unified Homenclature for Eph family receptorsand their ligands, the ephrins[J]. Cell, 1997, 90(3)： 403.
17、羅超，許明輝等，EphB2在腦膜瘤中表達(dá)與血管生成關(guān)系的研究[J]重慶醫(yī)學(xué)，2003,32 (3) ： 271
18.Adams RH Adams RH, Wilkinson GA，Weiss C, et al. Roles of ephrinB ligands andEphB receptors in cardiovascular development： demarcation of arterial/venousdomains，vascular morphogenesis* and sprouting angiogenesis[J]. Genes Dev, 1999，13(3)： 295
19、Wang HU, Chen ZF ’ Anderson D . Molecular distinetion and angiogenic interactionbetween embryonic arteries and veins revealed by ephrimB2 and its receptorEphB4[J]. Cell, 1998, 93(5)： 741
20、趙宏智，梁平.腫瘤組織血管內(nèi)皮生長(zhǎng)因子的血管生成作用[J].重慶醫(yī)學(xué)，2002，2(31)： 136.
21、郭新，李玉林，張麗紅，等.bFGF對(duì)胃癌血管新生和生物學(xué)行為的影響[J].吉林大學(xué)學(xué)報(bào)：醫(yī)學(xué)版，2002. 28(3)： 238-239.
22、姬永忠，羅梅，張煦，等.Survivin和bFGF在胃癌及腸化生組織中的表達(dá)及其與胃癌血管生成的關(guān)系[J].消化外科，2006, 5(41)： 239-241
23、劉棟才，李永國(guó)，楊竹林.VEGFmRNA和bFGFmRNA在原發(fā)性肝癌中的表達(dá)及意義[J].中國(guó)現(xiàn)代醫(yī)學(xué)雜志，2002, 12(16)： 56-57
24、李蘊(yùn)潛，鄒雅斌，李才，孫慶華人腦膜瘤bFGF的`表達(dá)與血管生成和細(xì)胞增殖能力的關(guān)系[J]，吉林大學(xué)學(xué)報(bào)，2002，28(3):266-268
25、陳堅(jiān)，易偉腦膜瘤微血管密度和堿性成纖維生長(zhǎng)因子及成纖維生長(zhǎng)因子受體-1的表達(dá)[J].中華實(shí)驗(yàn)外科雜志，2005，22 (6) ： 758
26、Belotti D, Paganoni P , Manenti L ’ et al ? Matrix metalloproteinaseMMP9 and MMP2induce the release of vascularendot helial growh factor (VEGF) by ovariancarcinomacells： implications for ascites formation[J]. Cancer Res, 2003，63(17)：5224-5229
27、劉安民，吳啟華，李方成，鐘志光，腦膜瘤腫瘤血管形成及瘤周水腫與基質(zhì)金屬蛋白酶-9表達(dá)的關(guān)系[J]，中華實(shí)驗(yàn)外科雜志，2005,22 (4) ： 465-466
28、Srecath T, Matrison LM, Stret ler-Staenson WG, et al. Expression of matrixmetalloproteinase genes in transformed rat cell lines of high and low metastaticpotential [ J].Cancer Res, 2002,52( 18): 4942-4947
29、Kamitami H, Masuzawa H, Kanazawa I, et al. Recurrence of convexity meningiomas:tumor cells in the arachnoid membrane.SurgNeurol,2001,56(4):228-235.
30、Papandr eou I, Pow ell A, Lim AL, et al. Cellar reactiontohypoxia: sensing and resp onding t o an adverse environment [ J]. M ut at Res, 2005，569(1-2): 87-100.
31、Folkman J. Tumor angiogenesis： therapeutic implication[J]. N Engl J Med, 1971,285(21)： 1182. 1186.
32、Pistolesi S, Boldrini L, Gisfredi S, et al. Angiogenesis in intraeranial meningJomas:immunohistochemieal and molecular study [J]. Neuropathol Appl Neumbiol, 2004，30(2)： 118-125.
33、王玉寶，劉艷萍，徐潤(rùn)之.缺氧誘導(dǎo)因子la、血管內(nèi)皮生長(zhǎng)因子與腦膜瘤血管生成、腫瘤惡性程度的關(guān)系[J].中華神經(jīng)外科雜志，2005 , 21(7)： 431
34、Jensen RL，Solean S, Bhayani MK, et a. Expression of hypoxia inducible factor-1 alphaand correlation with preoperative embolization of meningioma[J]. J Neurosurg, 2002,97(3)： 658-667
35、Kilic T, Bayn Y, Ozduman K, et al. Tenasein in meningiomas： expression iscorrelated with anaplasia* vascular endothelial growtii factor expression > andperitumoral edema but not with border shape. Neurosurgery, 2002? 51(1)： 183-192
36、OkadaY, ShimaT, YokoyamN, etal. Comparison of middle cerebral artery trunkocclusion by silicone cylinder embolization and by trapping. J Neurosurg，1998，58：492
37、李智偉，馬春曉，宋來(lái)君，徐國(guó)本，腦膜瘤肌腱蛋白的表達(dá)對(duì)腫瘤血管形成侵襲和瘤周水腫的影響[J]，醫(yī)藥論壇雜志，2009，27 (19) ： 8-10
38、李新軍，夏祥國(guó)，中期因子（MK)與腦膜瘤血管生成關(guān)系的研究，四川醫(yī)學(xué)，2009,30 (9) 1373-1374,
【臨床醫(yī)學(xué)專業(yè)碩士論文參考文獻(xiàn)】相關(guān)文章：